Ayda Ahmadi | Pancreatic Cancer | Best Researcher Award

Published on by Oncology

Ms. Ayda Ahmadi | Pancreatic Cancer | Best Researcher Award 

Student | Sahand University of Technology | Iran

Ms. Ayda Ahmadi is an emerging young researcher in biomedical and pharmaceutical engineering whose academic performance, early research productivity, and strong technical training collectively position her as a promising candidate for a Best Researcher Award. Currently pursuing her M.Sc. in Chemical Engineering with a specialization in Pharmaceutical Engineering at Sahand University of Technology, she holds a solid academic foundation built on a high-performing B.Sc. in Biomedical Engineering (Biomaterials) from Khayyam University. Her hands-on experience includes two extensive 240-hour internships at Samen Pharmaceutical Company—where she gained valuable skills in pharmaceutical formulation, sterile production systems, GMP-based quality control, and laboratory documentation—and in a Dental Prosthesis Laboratory, where she developed practical expertise in biomaterials fabrication relevant to tissue engineering and biomedical device applications. Ayda’s research output reflects her focus on advanced drug delivery systems, nanotechnology, and biomaterials, demonstrated through significant works such as the preparation and characterization of silica nanoparticles and aerogels for smart drug delivery, the design of targeted nanocarriers for anticancer drug delivery to pancreatic tumors, and the study of calcium sulfate for treating bone infections in diabetic patients. With manuscripts submitted and under review, she shows early publication initiative and a clear commitment to building a strong scientific portfolio. Her technical proficiency across COMSOL Multiphysics, MATLAB, Aspen HYSYS, OriginPro, and data management tools further enhances her research capability, supported by multiple certifications. Ayda’s research interests—spanning nanostructure functionalization, controlled antibiotic release, and biomedical applications of engineered materials—align strongly with global research priorities in precision medicine and therapeutic innovation. Motivated to participate in international conferences and collaborative projects, she demonstrates ambition, discipline, and scientific curiosity, making her a suitable and competitive candidate for recognition in young researcher or early-career researcher award categories.

Profile: ORCID

Featured Publications

  1. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2025). Preparation, characterization, and application of silica nanoparticles and silica aerogel in smart drug delivery systems. Manuscript submitted for publication.

  2. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2025). Design and development of smart nanocarriers for targeted delivery of anticancer drugs to pancreatic tumors: A review study. Manuscript under review.

  3. Ahmadi, A. (2024). Investigation of the effect of calcium sulfate in the treatment of bone infections in diabetic patients. Unpublished research project, Khayyam University.

  4. Ahmadi, A. (2024). Surface modification of silica aerogel for drug delivery in the treatment of bone infection in diabetic patients. Unpublished research study, Sahand University of Technology.

  5. Ahmadi, A., Souri, A., & Moghaddas, J. S. (2024). Development of functionalized nanostructures for controlled antibiotic release in infectious diseases. Unpublished manuscript.

Ms, Ayda Ahmadi’s research advances next-generation drug delivery systems and biomaterial-based therapeutics, contributing to safer, more effective treatments for cancer and infectious diseases. Her innovative work in nanotechnology and smart drug carriers supports global medical innovation by improving targeted therapy, reducing side effects, and addressing critical healthcare challenges.

Jaweher Bday | Cancer Research | Best Researcher Award

Published on by Oncology

Ms. Jaweher Bday | Cancer Research | Best Researcher Award 

PhD Student | Higher Institute of Biotechnology of Monastir | Tunisia

Ms. Jaweher Bday is a highly promising PhD researcher in biotechnology with a robust specialization in immuno-oncology, demonstrating strong potential and clear suitability for a Best Researcher Award through her scientific rigor, technical depth, and impactful research outputs. Her academic journey—from a bachelor’s degree in molecular and cellular biology, a research master’s in cell biology and physiology, to an ongoing PhD at the Higher Institute of Biotechnology of Monastir—illustrates continuous progression and dedication to cancer research. She has completed several competitive international research internships in leading laboratories in France, including the Bio PeroxIL Laboratory at the University of Burgundy and the INSERM U1307 Laboratory at the University of Nantes, enhancing her expertise in cell death mechanisms, tumor biology, and advanced molecular techniques. Her publication record is strong and growing, with peer-reviewed articles in recognized journals on topics such as arginase regulation in HPV infection, hybrid cell-death induction in breast cancer models, and the role of nitric oxide pathways in cervical carcinogenesis, along with an additional submitted manuscript on HPV circulating markers. Jaweher’s scientific maturity is evidenced by her active participation in conferences, including oral and poster presentations at national and international oncology and toxicology meetings, reflecting substantial dissemination of her research. Beyond laboratory excellence, she demonstrates leadership through major roles in the Tunisian Association of Biotechnology Students, including serving as President and spearheading scientific events and innovation-focused programs. Her teaching activities, spanning workshops, directed courses, and hands-on training, further showcase her commitment to academic development and knowledge transfer. Equipped with advanced laboratory skills, strong analytical proficiency using tools like FlowJo, ImageJ, SPSS, and GraphPad, along with extensive training in scientific writing, publishing, quality management, and pedagogy, she embodies the qualities of an emerging researcher with both scientific impact and community engagement. Overall, her achievements, productivity, international exposure, and leadership make her an excellent candidate for a Best Researcher Award.

Profile: ORCID

Featured Publications

  1. Souid, M., Bday, J., Souissi, S., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Toumi, D., Bergaoui, H., Zouari, I., Faleh, R., Zakhama, A., & Hassen, E. (2023). Arginase is upregulated in healthy women infected by oncogenic HPV types. Biomarkers, 28(7), 628–636.

  2. Bday, J., Souid, M., Pires, V., Gabbouj, S., Véjux, A., Lizard, G., & Hassen, E. (2025). Arginase activity inhibition with thymoquinone induces a hybrid type of cell death in MDA-MB-231 cell line. Journal of Biochemical and Molecular Toxicology, 39(2), e70130.

  3. Bday, J., Souid, M., Farhat, K. H., Macherki, Y., Ghedira, R., Gabbouj, S., Shini-Hadhri, S., Faleh, R., & Hassen, E. (2025). Involvement of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) levels in precancerous and cancerous cervical lesions. Nitric Oxide, 159, 176–185.

  4. Souid, M., Ghedira, R., Bday, J., Gabbouj, S., Shini-Hadhri, S., Hajji, A., Faleh, R., & Hassen, E. (Under review). Human Papillomavirus-16 circulating markers distribution among unvaccinated women. Infectious Diseases Now.

  5. Bday, J., Souid, M., Pires, V., Véjux, A., Lizard, G., & Hassen, E. (2025). Hybrid cell-death mechanisms in breast cancer: Insights from thymoquinone-mediated arginase inhibition. Manuscript in preparation.

Ms. Jaweher Bday’s work advances immuno-oncology by uncovering novel cellular and molecular mechanisms that can drive more precise cancer diagnostics and targeted therapies. Her research contributes to global health by improving understanding of HPV-related cancers and breast cancer biology, supporting innovations that can shape future clinical and translational applications. Through scientific leadership, teaching, and community engagement, she helps strengthen research capacity and fosters the next generation of biotechnology innovators.

Sanaz Alaeejahromi | Reproductive Cancer | Best Researcher Award

Published on by Oncology

Dr. Sanaz Alaeejahromi | Reproductive Cancer | Best Researcher Award

Assistant Professor | Shiraz University of Medical Sciences | Iran 

Dr. Sanaz Alaee is an accomplished reproductive biologist and clinical embryologist whose extensive academic, clinical, and research contributions make her an exceptional candidate for a Best Researcher Award. With over a decade of experience, she has built a distinguished career spanning reproductive toxicology, infertility treatment, ART technologies, and stem cell–based therapeutics. Her academic foundation includes a top-ranked PhD in Reproductive Biology, followed by faculty service at Shiraz University of Medical Sciences, where she has led the Reproductive Biology Department, directed the Reproductive Biology Lab, and currently serves as Director of the IVF Laboratory at Hazrat Zeinab Educational Medical Center. Her research portfolio is substantial, with more than 30 peer-reviewed publications covering critical topics such as implantation failure, ovarian and testicular toxicology, stem cell secretome therapy, PCOS biomarkers, assisted reproductive technologies, and oocyte/follicle maturation. A major highlight of her recent work includes a nationally funded project exploring extracellular vesicles from Wharton’s jelly mesenchymal stem cells for restoring fertility after chemotherapy—a promising direction for male infertility, especially among cancer survivors. She is internationally engaged, collaborating with researchers from the USA, UK, Australia, India, South Korea, Taiwan, UAE, and Kazakhstan, and remains active in global societies such as ESHRE, through which she is a certified Clinical Embryologist. Her editorial and peer-review influence is exemplary, with over 400 peer-reviews for high-impact journals, including Reproductive Sciences, Reproductive Toxicology, Scientific Reports, and PLOS ONE, demonstrating her commitment to scientific rigor and research integrity. Dr. Alaee has also contributed extensively to graduate education, curriculum development, and the supervision of MSc and PhD candidates. Her combined achievements in research innovation, clinical excellence, international collaboration, leadership, and scholarly service reflect a sustained and impactful contribution to reproductive biology, strongly supporting her suitability for a Best Researcher Award.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate 

Featured Publications

  1. Monsefi, M., Alaee, S., Moradshahi, A., & Rohani, L. (2010). Cadmium‐induced infertility in male mice. Environmental Toxicology: An International Journal, 25(1), 94–102.

  2. Fazeli, M., Hassanzadeh, P., & Alaei, S. (2011). Cadmium chloride exhibits a profound toxic effect on bacterial microflora of the mice gastrointestinal tract. Human & Experimental Toxicology, 30(2), 152–159.

  3. Neisy, A., Zal, F., Seghatoleslam, A., & Alaee, S. (2019). Amelioration by quercetin of insulin resistance and uterine GLUT4 and ERα gene expression in rats with polycystic ovary syndrome (PCOS). Reproduction, Fertility and Development, 31(2), 315–323.

  4. Alaee, S. (2017). Role of essential oil of Mentha spicata (spearmint) in addressing reverse hormonal and folliculogenesis disturbances in a polycystic ovarian syndrome in a rat model. Advanced Pharmaceutical Bulletin, 7(4), 651–654.

  5. Kargar-Abarghouei, E., Vojdani, Z., Hassanpour, A., Alaee, S., & others. (2018). Characterization, recellularization, and transplantation of rat decellularized testis scaffold with bone marrow-derived mesenchymal stem cells. Stem Cell Research & Therapy, 9(1), 324.

Dr. Alaee’s work advances reproductive science by integrating stem-cell therapies, toxicology insights, and cutting-edge ART technologies to improve fertility outcomes. Her research directly contributes to societal well-being by offering new hope for cancer survivors and infertile couples.

Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28

Aminah Alotaibi | Breast Cancer | Best Researcher Award

Published on by Oncology

Dr. Aminah Alotaibi | Breast Cancer | Best Researcher Award

Assistant Research Professor | King Abdulaziz city for science and technology | Saudi Arabia

Dr. Aminah Ghazi Alotaibi is a distinguished researcher affiliated with the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. With a Scopus h-index of 3, 4 indexed publications, and 58 citations, she has demonstrated consistent scholarly impact in the fields of hematology, stem cell biology, and molecular diagnostics. Her research primarily focuses on elucidating the phenotypic and molecular diversity of hematopoietic stem and progenitor cells (HSPCs) derived from cord blood and bone marrow, advancing the understanding of their biological significance and translational potential in clinical applications. Notably, her recent open-access article titled “Distinct Phenotypic and Molecular Characteristics of CD34− and CD34+ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications” (2025, Diagnostics) highlights her expertise in cellular characterization and regenerative medicine, offering valuable insights for stem cell-based therapies and transplantation science. Dr. Alotaibi’s collaborative network spans 23 co-authors, reflecting her active engagement in multidisciplinary and international scientific research. Her work integrates clinical hematology, genomics, and translational biomedical research, bridging the gap between laboratory discoveries and patient-centered innovations. Through her contributions, she aims to enhance diagnostic precision, therapeutic efficacy, and personalized medical approaches in hematologic and immune-related disorders. Dr. Alotaibi’s scholarly endeavors not only strengthen Saudi Arabia’s presence in global biomedical research but also contribute to the broader scientific community’s understanding of stem cell biology and its clinical potential.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

1. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2021). Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology, 457, 152806. Cited by: 36

2. Al-Saleh, I., Elkhatib, R., Al-Rajoudi, T., Al-Qudaihi, G., Manogarannogaran, P., Alotaibi, A. G., & others. (2020). Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. Chemosphere, 249, 126153. Cited by: 22

3. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2023). Tumour necrosis factor-alpha (TNF-α)-induced metastatic phenotype in colorectal cancer epithelial cells: Mechanistic support for the role of microRNA-21. Cancers, 15(3), 627. Cited by: 21

4. Gaafar, A., Hamza, F. N., Yousif, R., Shinwari, Z., Alotaibi, A. G., Iqniebi, A., & others. (2025). Distinct phenotypic and molecular characteristics of CD34− and CD34+ hematopoietic stem/progenitor cell subsets in cord blood and bone marrow samples: Implications for clinical applications. Diagnostics, 15(4), 447. Cited by: 1

5. Alotaibi, A. G. (2023). Effect of the inflammatory mediator TNF-α on colorectal cancer epithelial cells development and metastasis, role of dietary carcinogens and miRNA [Doctoral dissertation, Imperial College London]. Imperial College Repository.

Dr. Aminah Ghazi Alotaibi’s research advances global understanding of inflammation-driven carcinogenesis and stem cell biology, bridging molecular insights with clinical translation. Her work contributes to precision oncology, regenerative medicine, and the development of safer therapeutic strategies, fostering innovation that benefits both scientific progress and human health worldwide.

Permal Deo | Prostate Cancer | Best Researcher Award

Published on by Oncology

Dr. Permal Deo | Prostate Cancer | Best Researcher Award

Senior Lecturer | Clinical and Health Sciences, University of South Australia | Australia

Dr. Permal Deo is a distinguished food scientist and academic leader renowned for his contributions to nutrition, food biochemistry, and public health research. He holds a PhD in Food Biochemistry from Queen’s University Belfast, UK, where his doctoral work investigated the effects of food-derived advanced glycation end-products (AGEs) on oxidative stress and receptor activity in human cell lines. Complementing this, he earned a Master of Applied Science and Postgraduate Diploma from The University of Queensland, Australia, and a Bachelor of Science from The University of the South Pacific, Fiji. With over two decades of academic, research, and industry experience, Dr. Deo’s expertise encompasses food microbiology, food processing, functional foods, and the molecular pathways linking type 2 diabetes and Alzheimer’s disease. His research emphasizes the bioactivity of natural plant compounds and nutraceuticals in combating oxidative stress and inflammation, as well as the antimicrobial and food safety applications of electrochemically activated solutions. An accomplished mentor and research leader, he has supervised numerous postgraduate students and attracted more than AUD 2.5 million in competitive funding from prestigious bodies including the Australian Research Council, Diabetes Australia, and Horticulture Innovation. His extensive collaborations with institutions such as CSIRO, Monash University, and the University of Adelaide have advanced understanding in genome stability, indigenous food systems, and sustainable nutrition technologies. Widely recognized for his scholarly impact and leadership, Dr. Deo has presented at global scientific conferences and published influential studies in leading journals. His enduring scientific legacy is reflected through 944 citations, 57 documents, and an h-index of 19, underscoring his influential role in advancing the frontiers of food biochemistry, nutritional science, and biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Snelson, M., Tan, S. M., Clarke, R. E., De Pasquale, C., Thallas-Bonke, V., Deo, P., … & Coughlan, M. T. (2021). Processed foods drive intestinal barrier permeability and microvascular diseases. Science Advances, 7(14), eabe4841. Cited by: 148

2. Sim, D. P., Khazandi, M., Chan, W. Y., Deo, P., & Trott, D. J. (2019). Antimicrobial activity of thyme oil, oregano oil, thymol and carvacrol against sensitive and resistant microbial isolates from dogs with otitis externa. Veterinary Dermatology. Cited by: 106

3. Deo, P., Hewawasam, E., Karakoulakis, A., Claudie, D. J., Nelson, R., & Vemulpad, S. (2016). In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE), and digestive enzymes linked to diabetes. BMC Complementary and Alternative Medicine, 16(1), 435. Cited by: 61

4. Bergamin, A., Mantzioris, E., Cross, G., Deo, P., Garg, S., & Hill, A. M. (2019). Nutraceuticals: Reviewing their role in chronic disease prevention and management. Pharmaceutical Medicine, 33(4), 291–309. Cited by: 60

5. Fenech, M., Knasmueller, S., Knudsen, L. E., Kirsch-Volders, M., Deo, P., … & Bonassi, S. (2021). “Micronuclei and Disease” special issue: Aims, scope, and synthesis of outcomes. Mutation Research/Reviews in Mutation Research, 788, 108384. Cited by: 54

6. Ferro, S., Amorico, T., & Deo, P. (2018). Role of food sanitising treatments in inducing the ‘viable but nonculturable’ state of microorganisms. Food Control, 91, 321–329. Cited by: 54

Rui Liu | Tumor Radiobiology | Best Researcher Award

Published on by Oncology

Dr. Rui Liu | Tumor Radiobiology | Best Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

SCOPUS ID

GOOGLE SCHOLAR

🏥DR. RUI LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Rui Liu began her academic journey with a strong foundation in biomedical sciences, eventually earning a Ph.D. from a prestigious institution renowned for excellence in public health and molecular oncology. Her early research experiences centered on cellular biology and radiation mechanisms, which laid the groundwork for her specialization in tumor radiobiology and DNA damage repair (DDR).

🩺PROFESSIONAL ENDEAVORS

Currently serving as a Lecturer at the School of Public Health, Wenzhou Medical University, Dr. Liu has dedicated herself to cutting-edge cancer research. With over five years of hands-on laboratory experience, she has developed deep expertise in molecular biology, gene editing (CRISPR-Cas9), animal modeling, bioinformatics, and cellular imaging technologies. Her academic career reflects a balance between rigorous research and impactful teaching, mentoring the next generation of oncology researchers.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR RADIOBIOLOGY

Dr. Liu’s core research explores the molecular intricacies of radiotherapy resistance, with a focus on DNA damage repair pathways and ferroptosis in tumor cells. She has pioneered studies that unravel how long non-coding RNAs (lncRNAs) like MALAT1 influence cancer cell radiosensitivity, potentially leading to enhanced radiotherapy strategies. Her work contributes valuable insights into overcoming therapeutic resistance in breast cancer and other solid tumors.

🌍IMPACT AND INFLUENCE

Dr. Liu’s research has significantly advanced understanding in her field, evidenced by 445+ citations, an H-index of 12, and impactful publications in SCI-indexed journals. She is an active voice in the scientific community, engaging in collaborative research with Jilin University and contributing to national and provincial projects. Her affiliations with professional societies amplify her influence in radiological toxicology and environmental biophysics.

🏆 ACCOLADES AND RECOGNITION

Notable Awards:

  • 🎓 National Scholarship for Doctoral Excellence

  • 🌟 Recognition as a promising young investigator in radiobiology

🏆LEGACY AND FUTURE CONTRIBUTIONS

As an emerging leader in radiation oncology research, Dr. Liu aims to translate molecular findings into clinical applications that improve therapeutic outcomes. She mentors student researchers and continues to expand her interdisciplinary work on novel radiotherapy biomarkers, synthetic lethality, and non-coding RNA therapeutics. Her commitment ensures sustained contributions to precision oncology and translational cancer science.

🧬CONCLUSION

Dr. Rui Liu exemplifies the next generation of scientists transforming cancer treatment through molecular radiobiology. With a robust publication record, interdisciplinary collaborations, and active academic service, she is poised to leave a lasting impact on oncology research, education, and clinical innovation. Her ongoing efforts promise to redefine therapeutic strategies for radiation-resistant cancers.

📊🔬NOTABLE PUBLICATION:

Title: Metal ions overloading and cell death
Authors: Y. Lai, F. Gao, R. Ge, R. Liu, S. Ma, X. Liu
Journal: Cell Biology and Toxicology
Year: 2024

Title: Post‐translational modifications of protein in response to ionizing radiation
Authors: X. Liu, R. Liu, Y. Bai, H. Jiang, X. Fu, S. Ma
Journal: Cell Biochemistry and Function
Year: 2020

Title: The comparison of epidemiological characteristics between confirmed and clinically diagnosed cases with COVID-19 during the early epidemic in Wuhan, China
Authors: F. Shi, H. Wen, R. Liu, J. Bai, F. Wang, S. Mubarik, X. Liu, Y. Yu, Q. Hong, J. Cao, …
Journal: Global Health Research and Policy
Year: 2021

Title: Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population
Authors: R. Liu, L. Ning, X. Liu, H. Zhang, Y. Yu, S. Zhang, W. Rao, J. Shi, H. Sun, Q. Yu
Journal: Oncotarget
Year: 2017

Title: The challenges of precision radiotherapy technology to the traditional theory of radiobiology
Authors: S. Ma, Z. Liang, Q. Chen, R. Liu, Y. Guo, X. Liu
Journal: Chinese Journal of Radiological Medicine and Protection
Year: 2019

Title: Tumor-associated macrophages in radiotherapy: Mechanisms of polarization, immune regulation and therapeutic strategies
Authors: S. Ma, Z. Liang, X. Liu, R. Liu
Journal: Frontiers in Oncology
Year: 2023

Ohidul Alam | Cancer Science | Best Researcher Award

Published on by Oncology

Dr. Ohidul Alam | Cancer Science | Best Researcher Award

Jiangsu University | China

AUTHOR PROFILE

GOOGLE SCHOLAR

ORCID ID

🏥DR. OHIDUL ALAM: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ohidul Alam began his academic journey with a BSc (Hons.) in Environmental Science at the Institute of Forestry and Environmental Sciences, University of Chittagong, Bangladesh. He further completed his MS in Environmental Science at the same institute. His quest for global academic excellence led him to Tongji University, Shanghai, where he earned his MEng in Environmental Engineering, supported by the UNEP-Tongji Institute of Environment for Sustainable Development. He achieved his Ph.D. in Environmental Engineering from East China University of Science and Technology, focusing on sustainable materials and pollution control.

🩺PROFESSIONAL ENDEAVORS

Dr. Alam’s professional journey is marked by diverse roles across academia, consultancy, and environmental policy. He currently serves as a Post-doctoral Research Fellow at the School of the Environment and Safety Engineering, Jiangsu University, China, where he leads cutting-edge research on heavy metals, microplastics, and hazardous waste management.

Prior roles include:

  • Environmental Officer at the Sustainable Enterprise Project (SEP), Bangladesh

  • Consultant at DM WATCH (focusing on climate change and hazard risk management)

  • Manager at Aurora Consultant Limited

  • Research Assistant for GIZ, IUCN, and Japan-funded environmental and socio-economic projects

  • Guest Lecturer at Chattogram Polytechnic Institute

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON ENVIRONMENT

While Dr. Alam’s primary research is in environmental engineering and waste management, his work has strong implications for cancer science through the lens of public health and environmental carcinogen exposure. His investigation into heavy metals, microplastics, and pollutants directly aligns with cancer risk assessment, particularly regarding chronic exposure to hazardous waste, antibiotic resistance genes, and environmental toxins in water and soil.

His postdoctoral work, titled “Heavy Metals, Microplastics, and Waste Management: Environmental and Health Perspectives”, contributes to the understanding of environmental triggers in non-communicable diseases including cancer.

🌍IMPACT AND INFLUENCE

Dr. Alam has established himself as a globally engaged researcher, presenting in international conferences and contributing to policy-relevant research in South Asia and China. His work informs sustainable practices and evidence-based environmental governance.

  • Participated in leading workshops on Climate Change, LCA, and Solid Waste Management

  • Engaged with international initiatives under UNEP, USAID, and GIZ

  • Actively contributes to academic capacity building in Bangladesh and China

🔑 Keywords: International Collaboration, Environmental Policy, South Asia, Global Sustainability

📚 ACADEMIC CITATIONS, ACCOLADES, AND RECOGNITION

Dr. Alam has published over 31 peer-reviewed journal articles (16 SCI-indexed, 9 open-access international, 3 national journals, and 3 technical notes). Additionally, he has authored 13 international conference papers. He serves as a reviewer for respected journals such as:

  • Journal of Environmental Management

  • Environmental Research

  • Sustainable Cities and Society

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Alam’s research aims to bridge environmental engineering with health and sustainability, particularly focusing on pollution-derived health risks. He envisions developing green materials, safer waste disposal technologies, and cancer risk-reducing environmental frameworks. His mentorship of peers and support for junior researchers highlight his commitment to capacity building and knowledge sharing.

🧬CONCLUSION

Dr. Ohidul Alam stands as a multidisciplinary environmental researcher whose work integrates science, policy, and public health. His academic rigor, international exposure, and dedication to sustainable development make him a formidable contributor to environmental and health sciences, with growing relevance in the domain of environmental oncology and pollution-induced diseases.

📊🔬NOTABLE PUBLICATION:

Influences of chemically controlled Ca-bearing minerals in chitosan on Pb²⁺ removal efficiency

Author(s): Ohidul Alam, Xiuchen Qiao
Journal: Journal of Environmental Health Science and Engineering
Year: 2020

The effect of Ca-bearing contents in chitosan on Pb²⁺, Cd²⁺ and Cu²⁺ adsorption and its adsorption mechanism

Author(s): Ohidul Alam, Xiuchen Qiao, Tapan Kumar Nath
Journal: Journal of Environmental Health Science and Engineering
Year: 2020

A preliminary life cycle assessment on healthcare waste management in Chittagong City, Bangladesh

Author(s): Ohidul Alam, A. Mosharraf
Journal: International Journal of Environmental Science and Technology
Year: 2020

An in-depth review on municipal solid waste management, treatment and disposal in Bangladesh

Author(s): Ohidul Alam, Xiuchen Qiao
Journal: Sustainable Cities and Society
Year: 2020

Determination of the selected heavy metal and metalloid contents in various types of plastic bags

Author(s): Ohidul Alam, Li Yang, Xu Yanchun
Journal: Journal of Environmental Health Science and Engineering
Year: 2019

Prof. Yingfen Ying | Tumors | Women Researcher Award

Published on by Oncology

Prof. Yingfen Ying | Tumors | Women Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

Scopus

PROFESSOR YINGFEN YING: A DISTINGUISHED MEDICAL PROFESSIONAL 👩‍⚕️🌍

EARLY ACADEMIC PURSUITS 🎓✨

Professor Yingfen Ying embarked on her academic journey with a strong focus on medical sciences, demonstrating an early aptitude for research and clinical excellence. Her academic foundation was fortified through rigorous education at Wenzhou Medical University, where she gained critical knowledge and skills that paved the way for her distinguished career. She further enriched her expertise as a visiting scholar at the University of British Columbia in Canada, a testament to her global academic vision.

PROFESSIONAL ENDEAVORS 💼🏥

Professor Ying has made significant strides as an Associate Chief Physician and master’s supervisor at Wenzhou Medical University. Her roles extend to various esteemed positions, including:

  • Member of the Obstetrics and Gynecology Rehabilitation Committee, Chinese Rehabilitation Medicine Association.
  • Vice Chairwoman of the Youth Committee, Reproductive Medicine Branch, Zhejiang Society of Traditional Chinese and Western Medicine.
  • Member of the Obstetrics and Gynecology Branch, Zhejiang Society of Translational Medicine.
    She is also affiliated with prominent international organizations, such as the American Society of Reproductive Medicine and the European Society of Human Reproduction and Embryology.

CONTRIBUTIONS AND RESEARCH FOCUS 🔬📚

Professor Ying’s primary research interests center on the mechanistic study of environmental endocrine disruptors and reproductive endocrine diseases. Her investigations delve into the interplay between environmental factors and hormonal imbalances, significantly advancing our understanding of infertility diseases. She has led multiple national and international research projects, including those funded by the National Natural Science Foundation of China.

IMPACT AND INFLUENCE 🌟🌏

Professor Ying’s work has had far-reaching impacts in the field of reproductive medicine. She has authored nearly 30 SCI-indexed papers, contributing valuable insights and advancements to the global medical community. Her research continues to influence clinical practices and guide innovative therapeutic approaches for infertility.

ACADEMIC CITES AND PATENT ACHIEVEMENTS 📜🔑

Professor Ying’s extensive research portfolio has garnered numerous citations in high-impact journals. Additionally, she holds a European patent, exemplifying her contributions to advancing medical technology and treatment methodologies on a global scale.

LEGACY AND FUTURE CONTRIBUTIONS 🌟🚀

As a trailblazer in reproductive medicine, Professor Yingfen Ying’s legacy is defined by her commitment to advancing medical science, mentoring future generations, and improving patient outcomes. Her ongoing projects and international collaborations promise continued breakthroughs, ensuring her work remains at the forefront of reproductive health and endocrine research.

ADDITIONAL HIGHLIGHTS 🌐📖

  • Active member of youth committees in Zhejiang’s medical and scientific communities, fostering innovation and development among emerging scholars.
  • Her dedication to integrating traditional Chinese and Western medicine highlights a holistic approach to patient care and research.
  • International affiliations reflect her commitment to global medical advancements, strengthening ties between diverse medical communities.

CONCLUSION 🌟🏆

Professor Yingfen Ying exemplifies excellence in the fields of reproductive medicine and endocrine research. Her dedication to uncovering the mechanisms of infertility diseases and environmental endocrine disruptors has advanced both science and clinical practice. Through her leadership roles, impactful publications, and international collaborations, she has established herself as a global authority and advocate for holistic and innovative approaches to healthcare.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Halogen atoms determine the inhibitory potency of halogenated bisphenol A derivatives on human and rat placental 11β-hydroxysteroid dehydrogenase 2
    Authors: Shi, L., Zhang, B., Ying, Y., Ge, R.-S., Liu, Y.
    Journal: Food and Chemical Toxicology
    Year: 2023

 

  • Title: Inhibitory effects of parabens on human and rat 17β-hydroxysteroid dehydrogenase 1: Mechanisms of action and impact on hormone synthesis
    Authors: Chen, Z., Gong, C., Tang, Y., Ge, R.-S., Ying, Y.
    Journal: Toxicology
    Year: 2024

 

  • Title: Per- and polyfluoroalkyl substances inhibit human and rat 17β-hydroxysteroid dehydrogenase 1: Quantitative structure-activity relationship and molecular docking analysis
    Authors: Wen, C., Chen, H., Tang, Y., Chen, C., Chen, S.
    Journal: Ecotoxicology and Environmental Safety
    Year: 2024

 

  • Title: Leydig cell development in pubertal male rats is blocked by perfluorotetradecanoic acid through decreasing AMPK-mTOR-autophagy pathway
    Authors: Tang, Y., Shi, L., Wang, S., Ge, R.-S., Ying, Y.
    Journal: Toxicology Letters
    Year: 2023

 

  • Title: Structure-activity relationship and in silico docking analysis of dicarboximide fungicides on 17β-hydroxysteroid dehydrogenase 1 of human, rat, and pig
    Authors: Chen, H., Chen, S., Tang, Y., Ge, R.-S., Duan, P.
    Journal: Ecotoxicology and Environmental Safety
    Year: 2025

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Published on by Oncology

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Kansai Medical University Hospital | Japan

AUTHOR PROFILE

Scopus

ORCID Id

🧑‍🎓 EARLY ACADEMIC PURSUITS 📚

Dr. Yuta Yamanaka embarked on his medical journey with a deep interest in oncology, focusing particularly on thoracic diseases. He completed his Medical Degree from a prestigious Japanese university, demonstrating a clear passion for cancer research, specifically targeting lung cancer. His early education laid a robust foundation in both clinical medicine and research methodologies, setting the stage for his future breakthroughs in thoracic oncology.

🩺 PROFESSIONAL ENDEAVORS 🏥

Dr. Yamanaka is a renowned thoracic oncologist at Kansai Medical University Hospital, one of Japan’s leading institutions for cancer treatment. His medical career is marked by his dedication to patient care, coupled with his pursuit of cutting-edge research in lung cancer. As a departmental leader, Dr. Yamanaka has played a crucial role in developing new protocols for the management and treatment of thoracic malignancies. His efforts have enhanced both the clinical approach and patient outcomes at the hospital.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LUNG CANCER🔍

Dr. Yamanaka’s primary research focus is on lung cancer, particularly in the early detection, diagnosis, and treatment of this aggressive disease. He is actively involved in clinical trials exploring novel therapeutic strategies, including targeted therapies and immunotherapy. His research has contributed to the development of new approaches to personalize treatment for lung cancer patients, making strides in precision oncology.

Additionally, Dr. Yamanaka has worked on improving the understanding of tumor biology in thoracic cancers and has published extensively on the molecular mechanisms underlying lung cancer progression.

🌍 IMPACT AND INFLUENCE 💡

Dr. Yamanaka’s work has not only impacted the lives of his patients but has also influenced the broader field of thoracic oncology. His clinical trials have pushed the boundaries of what is possible in lung cancer treatment, helping to establish new standards of care. Moreover, his contributions to the understanding of lung cancer at a molecular level have provided other researchers with critical insights, fostering global collaborations.

🏆 ACADEMIC CITES AND RECOGNITION 📜

Dr. Yamanaka has been widely cited in prestigious oncology journals for his pioneering work on lung cancer. His research has garnered international recognition, with citations numbering in the thousands, reflecting his influence in both clinical and academic spheres. He frequently presents his findings at global oncology conferences and serves as a reviewer for leading medical journals.

🔮 LEGACY AND FUTURE CONTRIBUTIONS 🌟

Looking forward, Dr. Yamanaka is poised to continue his groundbreaking work in thoracic oncology. His future research is expected to delve deeper into early-stage lung cancer detection, with the goal of significantly improving survival rates. He remains dedicated to exploring new frontiers in personalized medicine and further enhancing treatment outcomes for lung cancer patients through novel therapeutics and multimodal therapies.

Dr. Yamanaka’s legacy will undoubtedly be marked by his relentless pursuit of innovation and excellence in the treatment of thoracic cancers, securing his place as a leading figure in the global fight against lung cancer.

Dr. Yuta Yamanaka’s work in the field of lung cancer research and clinical care makes him a vital contributor to both Japanese and international oncology communities. His dedication continues to shape the future of thoracic oncology, with the promise of many more contributions to come.

✨ CONCLUSION 🎯

Dr. Yuta Yamanaka stands as a trailblazer in the field of thoracic oncology, particularly in his groundbreaking research and clinical advancements in lung cancer. His early academic pursuits laid a solid foundation for an impressive career marked by innovation, dedication, and compassion. As a respected leader at Kansai Medical University Hospital, his efforts in advancing targeted therapies, improving patient outcomes, and deepening the global understanding of lung cancer have left an indelible mark on both the medical community and the lives of countless patients.

 

📊🔬NOTABLE PUBLICATION:

 

    • Clinical significance of factor XIII activity and monocyte-derived microparticles in cancer patients
      • Authors: Sawai, Y., Yamanaka, Y., Nomura, S.
      • Journal: Vascular Health and Risk Management
      • Year: 2020

     

    • Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study
      • Authors: Takeda, T., Yamada, T., Kunimatsu, Y., Kurata, T., Takayama, K.
      • Journal: Cancers
      • Year: 2023

     

    • Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older
      • Authors: Yagishita, S., Yamanaka, Y., Kurata, T., Mizugaki, H., Hamada, A.
      • Journal: Clinical Pharmacology and Therapeutics
      • Year: 2024

     

    • Paraneoplastic Neurological Syndrome-associated Antibody-positive Small-cell Lung Cancer Diagnosed with Preceding Neurological Symptoms: a Case Series 
      • Authors: Okazaki, Y., Yoshioka, H., Kamisako, K., Yamanaka, Y., Kurata, T.
      • Journal: Japanese Journal of Lung Cancer
      • Year: 2024

     

    • Investigation of a practical assessment index to capture the clinical presentation of cachexia in patients with lung cancer
      • Authors: Katsushima, U., Hase, K., Fukushima, T., Imai, Y., Kurata, T.
      • Journal: Japanese Journal of Clinical Oncology
      • Year: 2024